Ymmunobio Appoints Dr. Michel Janicot as Chief Development Officer
RIEHEN, SWITZERLAND, January 10, 2023 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of innovative...
top of page
Search
- Oct 19, 2022
- 1 min
Ymmunobio’s abstract accepted for poster presentation at SITC in Boston, November 2022
RIEHEN, SWITZERLAND, October 18, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM...
- Oct 19, 2022
- 1 min
Ymmunobio selected by BIO-Europe to participate in its Start-up Spotlight Session
RIEHEN, SWITZERLAND, October 18, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM...
bottom of page